Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

The Full Hormone Panel and Upsell

SHBG, Albumin, LH/FSH, Estradiol (Sensitive vs Standard E2)

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Individual analyte assays run in CLIA labs

Reference only. Not medical advice.

What can go wrong

Using a standard rather than sensitive estradiol assay in men can mislead and prompt unnecessary aromatase-inhibitor use, which carries its own risks (bone, lipids). Over-broad panels increase the chance of incidental out-of-range values that drive low-value treatment.

This is something to take to a clinician. The Atlas can tell you what is known about the full hormone panel and upsell in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Beyond total testosterone, a workup may include SHBG and albumin (the binding proteins behind free/bioavailable T), LH and FSH (to localize the problem to testis vs pituitary), and estradiol. Estradiol must be measured by a sensitive (LC-MS/MS) assay in men; standard estradiol immunoassays were designed for the higher levels in women and are unreliable in the male range. These analytes are clinically legitimate when there is a real diagnostic question, but optimization marketing often bundles a long panel and reframes every out-of-'optimal' value as a problem to be treated - frequently with add-on agents like aromatase inhibitors.

The companion labs that make a borderline result look like a syndrome.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Localizing primary vs secondary hypogonadism (LH/FSH)
  • Computing free/bioavailable testosterone (SHBG, albumin)
  • Monitoring estradiol on therapy with a sensitive assay

How it works

SHBG and albumin determine how much testosterone is free; LH and FSH indicate whether low testosterone is testicular (high LH/FSH) or central (low/normal LH/FSH); estradiol, derived from testosterone via aromatase, is relevant on therapy but only meaningful when measured by a sensitive method in the low male range. Together these refine, rather than inflate, the diagnostic picture when used judiciously.

How a legitimate panel becomes an upsell

A standard (non-sensitive) estradiol immunoassay can over-read estradiol in men, which some clinics use to justify aromatase inhibitors that are not guideline-supported for routine TRT. A long 'optimization' panel multiplies the number of values that can fall outside an aspirational band, each one a hook for an add-on product or coaching tier. The disciplined use is targeted: order LH/FSH to localize the lesion, SHBG/albumin to interpret free T, and sensitive estradiol only when symptoms warrant - not a reflexive battery framed as comprehensive care.

What people get wrong

  • Often saidEvery man on TRT needs his estradiol crushed with an aromatase inhibitor

    ActuallyRoutine AI use is not guideline-endorsed; estradiol has physiological roles, and standard assays often over-report it in men, manufacturing a problem.

  • Often saidA bigger panel is more thorough care

    ActuallyIndiscriminate testing increases false-positive out-of-range values; targeted analytes answer specific questions.

Who profits, and who pushes back

  • Shalender Bhasin, MD

    Pushes backChair, Endocrine Society 2018 testosterone guideline

    Laboratory evaluation should be targeted to the clinical question, not expanded to generate findings.

  • Endocrine Society

    Pushes back2018 guideline

    Estradiol in men should be interpreted using a sensitive, validated assay.

What we do not know

  • How often do optimization clinics use standard rather than sensitive estradiol assays?
  • What share of AI prescriptions are driven by assay over-reporting rather than symptoms?

At a glance

Binding proteins
SHBG and albumin (drive free T)
Pituitary axis markers
LH and FSH
Estradiol caveat
Use sensitive/LC-MS/MS assay in men
Upsell risk
Long panels reframe normal as 'suboptimal'

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about The Full Hormone Panel and Upsell. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Endocrine Society guideline (workup analytes)2018

    Supports LH/FSH to classify hypogonadism and free T estimation via SHBG when indicated

  • Sensitive estradiol method literature (e.g., Mayo/CDC)2010s

    Standard estradiol immunoassays are unreliable at low male concentrations; LC-MS/MS sensitive assay recommended

  • AUA guideline (selective testing)2018

    Endorses targeted laboratory evaluation rather than indiscriminate panels